cannabis
Resetting Cannabis Benefits Doesn’t Cut Taxes vs Pharma Returns
A recent Safe Harbor Financial model shows that reclassifying cannabis under Schedule III trims corporate tax bills by about 15%, far short of the 35% relief pharma firms now enjoy. The shift promises modest savings, but the broader financial picture remains uneven. In my work with cannabis operators, I have